Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct 29;11(11):4176-92.
doi: 10.3390/md11114176.

Anti HSV-1 activity of halistanol sulfate and halistanol sulfate C isolated from Brazilian marine sponge Petromica citrina (Demospongiae)

Affiliations

Anti HSV-1 activity of halistanol sulfate and halistanol sulfate C isolated from Brazilian marine sponge Petromica citrina (Demospongiae)

Tatiana da Rosa Guimarães et al. Mar Drugs. .

Abstract

The n-butanol fraction (BF) obtained from the crude extract of the marine sponge Petromica citrina, the halistanol-enriched fraction (TSH fraction), and the isolated compounds halistanol sulfate (1) and halistanol sulfate C (2), were evaluated for their inhibitory effects on the replication of the Herpes Simplex Virus type 1 (HSV-1, KOS strain) by the viral plaque number reduction assay. The TSH fraction was the most effective against HSV-1 replication (SI = 15.33), whereas compounds 1 (SI = 2.46) and 2 (SI = 1.95) were less active. The most active fraction and these compounds were also assayed to determine the viral multiplication step(s) upon which they act as well as their potential synergistic effects. The anti-HSV-1 activity detected was mediated by the inhibition of virus attachment and by the penetration into Vero cells, the virucidal effect on virus particles, and by the impairment in levels of ICP27 and gD proteins of HSV-1. In summary, these results suggest that the anti-HSV-1 activity of TSH fraction detected is possibly related to the synergic effects of compounds 1 and 2.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of halistanol sulfate (1) and halistanol sulfate C (2).
Figure 2
Figure 2
Structures of halistanol sulfate (1) and derivatives halistanol sulfates A to H (29).
Figure 3
Figure 3
Effects of samples obtained from Petromica citrina on HSV-1 (KOS strain) proteins expression.
Figure 4
Figure 4
Overview of the strategy used for the purification of sulfate halistanol (compound 1) and sulfate halistanol C (compound 2) from the butanol fraction of Petromica citrina.

Similar articles

Cited by

References

    1. Nakakawa E., Reynold S.J. The management of herpes simplex virus infections in HIV infected patients: Current issues and the role of cidofovir. Virus Adapt. Treat. 2011;3:35–43.
    1. Sagar S., Kaur M., Minneman K.P. Antiviral lead compounds from marine sponges. Mar. Drugs. 2010;8:2619–2638. doi: 10.3390/md8102619. - DOI - PMC - PubMed
    1. Snoeck R. Antiviral therapy of herpes simplex. Int. J. Antimicrob. Agents. 2000;16:157–159. doi: 10.1016/S0924-8579(00)00233-8. - DOI - PubMed
    1. De Clercq E. Antivirals: Past, present and future. Biochem. Pharmacol. 2013;85:727–744. doi: 10.1016/j.bcp.2012.12.011. - DOI - PubMed
    1. Mayer A.M.S., Rodríguez A.D., Berlinck R.G.S., Fusetani N. Marine pharmacology in 2007–8: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneous mechanisms of action. Comp. Biochem. Physiol. Part C Toxicol. Pharmacol. 2011;153:191–222. doi: 10.1016/j.cbpc.2010.08.008. - DOI - PMC - PubMed

Publication types

LinkOut - more resources